{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:55:37Z","timestamp":1761490537912,"version":"build-2065373602"},"reference-count":85,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T00:00:00Z","timestamp":1711756800000},"content-version":"vor","delay-in-days":2190,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.7861\/clinmedicine.18-2-138","type":"journal-article","created":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T04:16:36Z","timestamp":1522988196000},"page":"138-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Drug therapies in chronic heart failure: a focus on reduced ejection fraction"],"prefix":"10.1016","volume":"18","author":[{"given":"Helena","family":"Bolam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geraint","family":"Morton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul R","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.7861\/clinmedicine.18-2-138_bib1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1053\/euhj.2000.2289","article-title":"Coronary artery disease as the cause of incident heart failure in the population","volume":"22","author":"Fox","year":"2001","journal-title":"Eur Heart J"},{"key":"10.7861\/clinmedicine.18-2-138_bib2","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archinte.161.7.996","article-title":"Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study","volume":"161","author":"He","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.7861\/clinmedicine.18-2-138_bib3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.289.2.194","article-title":"Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic","volume":"289","author":"Redfield","year":"2003","journal-title":"JAMA"},{"issue":"Suppl 2","key":"10.7861\/clinmedicine.18-2-138_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/europace\/eur081","article-title":"What are the costs of heart failure?","volume":"13","author":"Braunschweig","year":"2011","journal-title":"Europace"},{"year":"2017","series-title":"National heart failure audit April 2015 \u2013 March 2016","author":"Donkor","key":"10.7861\/clinmedicine.18-2-138_bib5"},{"key":"10.7861\/clinmedicine.18-2-138_bib6","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.7861\/clinmedicine.18-2-138_bib7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0735-1097(92)90167-L","article-title":"The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure","volume":"20","author":"Packer","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.7861\/clinmedicine.18-2-138_bib8","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"CONSENSUS Trial Study Group","year":"1987","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.18-2-138_bib9","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","article-title":"Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials","volume":"273","author":"Garg","year":"1995","journal-title":"JAMA"},{"key":"10.7861\/clinmedicine.18-2-138_bib10","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/S0735-1097(01)01161-5","article-title":"Are all angiotensin-converting enzyme inhibitors interchangeable?","volume":"37","author":"Furberg","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.7861\/clinmedicine.18-2-138_bib11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/00005344-200401000-00009","article-title":"Twice-daily administration of a long-acting angiotensin-converting enzyme inhibitor has greater effects on neurohumoral factors than a once-daily regimen in patients with chronic congestive heart failure","volume":"43","author":"Hirooka","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.7861\/clinmedicine.18-2-138_bib12","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.18-2-138_bib13","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.7861\/clinmedicine.18-2-138_bib14","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.7861\/clinmedicine.18-2-138_bib15","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/jama.2013.1954","article-title":"Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial","volume":"309","author":"Gheorghiade","year":"2013","journal-title":"JAMA"},{"key":"10.7861\/clinmedicine.18-2-138_bib16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","author":"CIBIS-II Investigators and Committees","year":"1999","journal-title":"Lancet"},{"key":"10.7861\/clinmedicine.18-2-138_bib17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"10.7861\/clinmedicine.18-2-138_bib18","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1001\/jama.289.6.712","article-title":"Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study","volume":"289","author":"Krum","year":"2003","journal-title":"JAMA"},{"key":"10.7861\/clinmedicine.18-2-138_bib19","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","author":"MERIT-HF Study Group","year":"1999","journal-title":"Lancet"},{"key":"10.7861\/clinmedicine.18-2-138_bib20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial","volume":"362","author":"Poole-Wilson","year":"2003","journal-title":"Lancet"},{"key":"10.7861\/clinmedicine.18-2-138_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12471-012-0366-7","article-title":"Beta-blocker therapy in unstable severe heart failure, evidence or experience?","volume":"21","author":"Meuwese","year":"2013","journal-title":"Neth Heart J"},{"key":"10.7861\/clinmedicine.18-2-138_bib22","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.7861\/clinmedicine.18-2-138_bib23","doi-asserted-by":"crossref","first-page":"784","DOI":"10.7326\/0003-4819-150-11-200906020-00006","article-title":"Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure","volume":"150","author":"McAlister","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.7861\/clinmedicine.18-2-138_bib24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.18-2-138_bib25","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"year":"2010","series-title":"Chronic heart failure in adults: management","key":"10.7861\/clinmedicine.18-2-138_bib26"},{"key":"10.7861\/clinmedicine.18-2-138_bib27","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.18-2-138_bib28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/clc.20324","article-title":"A comparison of the aldosterone-blocking agents eplerenone and spironolactone","volume":"31","author":"Struthers","year":"2008","journal-title":"Clin Cardiol"},{"key":"10.7861\/clinmedicine.18-2-138_bib29","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1751-7176.2011.00495.x","article-title":"Spironolactone is more effective than eplerenone at lowering blood pressure in patients with primary aldosteronism","volume":"13","author":"Bloch","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.7861\/clinmedicine.18-2-138_bib30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1755-5922.2012.00321.x","article-title":"Resting heart rate and outcomes in patients with cardiovascular disease: where do we currently stand?","volume":"31","author":"Menown","year":"2013","journal-title":"Cardiovasc Ther"},{"key":"10.7861\/clinmedicine.18-2-138_bib31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1161\/CIRCHEARTFAILURE.113.000429","article-title":"Association of heart rate at hospital discharge with mortality and hospitalizations in patients with heart failure","volume":"7","author":"Habal","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.7861\/clinmedicine.18-2-138_bib32","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.ijcard.2012.06.116","article-title":"Discontinuation of beta-blockers in cardiovascular disease: UK primary care cohort study","volume":"167","author":"Kalra","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.7861\/clinmedicine.18-2-138_bib33","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ijcard.2017.08.001","article-title":"Quality of life improvement in older patients with heart failure initiated on ivabradine: results from the UK multi-centre LIVE:LIFE prospective cohort study","volume":"249","author":"Zachariah","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.7861\/clinmedicine.18-2-138_bib34","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.18-2-138_bib35","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"Investigators","year":"1992","journal-title":"N Engl J Med"},{"year":"2016","series-title":"Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction","key":"10.7861\/clinmedicine.18-2-138_bib36"},{"key":"10.7861\/clinmedicine.18-2-138_bib37","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0167-5273(01)00600-3","article-title":"Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials","volume":"82","author":"Faris","year":"2002","journal-title":"Int J Cardiol"},{"key":"10.7861\/clinmedicine.18-2-138_bib38","doi-asserted-by":"crossref","first-page":"000547","DOI":"10.1136\/openhrt-2016-000547","article-title":"Specialist intervention is associated with improved patient outcomes in patients with decompensated heart failure: evaluation of the impact of a multidisciplinary inpatient heart failure team","volume":"4","author":"Masters","year":"2017","journal-title":"Open Heart"},{"key":"10.7861\/clinmedicine.18-2-138_bib39","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/ki.1984.153","article-title":"Bumetanide and furosemide in heart failure","volume":"26","author":"Brater","year":"1984","journal-title":"Kidney Int"},{"key":"10.7861\/clinmedicine.18-2-138_bib40","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/j.1552-4604.1981.tb05684.x","article-title":"Clinical trial of bumetanide versus furosemide in patients with congestive heart failure","volume":"21","author":"Konecke","year":"1981","journal-title":"J Clin Pharmacol"},{"key":"10.7861\/clinmedicine.18-2-138_bib41","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/j.1875-9114.1997.tb03681.x","article-title":"Variable furosemide absorption and poor predictability of response in elderly patients","volume":"17","author":"Murray","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.7861\/clinmedicine.18-2-138_bib42","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2008.05.068","article-title":"Importance of venous congestion for worsening of renal function in advanced decompensated heart failure","volume":"53","author":"Mullens","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.7861\/clinmedicine.18-2-138_bib43","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCHEARTFAILURE.111.963413","article-title":"Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function","volume":"5","author":"Metra","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.7861\/clinmedicine.18-2-138_bib44","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.18-2-138_bib45","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study","volume":"314","author":"Cohn","year":"1986","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.18-2-138_bib46","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure","volume":"336","author":"Digitalis Investigation Group","year":"1997","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.18-2-138_bib47","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.amjcard.2008.06.068","article-title":"Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the Digitalis Investigation Group trial","volume":"103","author":"Digitalis Investigation Group","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.7861\/clinmedicine.18-2-138_bib48","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.18-2-138_bib49","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"10.7861\/clinmedicine.18-2-138_bib50","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/j.jacc.2006.03.034","article-title":"Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study","volume":"47","author":"Scirica","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.7861\/clinmedicine.18-2-138_bib51","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(08)61239-8","article-title":"Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"10.7861\/clinmedicine.18-2-138_bib52","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1161\/01.CIR.83.1.52","article-title":"Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group","volume":"83","author":"Goldstein","year":"1991","journal-title":"Circulation"},{"key":"10.7861\/clinmedicine.18-2-138_bib53","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0002-8703(00)90224-2","article-title":"Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines","volume":"139","author":"de Vries","year":"2000","journal-title":"Am Heart J"},{"key":"10.7861\/clinmedicine.18-2-138_bib54","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJM199610103351504","article-title":"Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group","volume":"335","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.18-2-138_bib55","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1161\/CIRCULATIONAHA.105.580506","article-title":"Renal function as a predictor of outcome in a broad spectrum of patients with heart failure","volume":"113","author":"Hillege","year":"2006","journal-title":"Circulation"},{"year":"2017","series-title":"British Society for Heart Failure, Think Kidneys","author":"The Renal Association","key":"10.7861\/clinmedicine.18-2-138_bib56"},{"key":"10.7861\/clinmedicine.18-2-138_bib57","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1016\/j.jacc.2017.04.001","article-title":"Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure","volume":"69","author":"Kotecha","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.7861\/clinmedicine.18-2-138_bib58","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa1001337","article-title":"Lenient versus strict rate control in patients with atrial fibrillation","volume":"362","author":"Van Gelder IC","year":"2010","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.18-2-138_bib59","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jchf.2014.01.005","article-title":"Is heart rate important for patients with heart failure in atrial fibrillation?","volume":"2","author":"Cullington","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.7861\/clinmedicine.18-2-138_bib60","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0002-9149(02)03104-1","article-title":"Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure","volume":"91","author":"Gattis","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.7861\/clinmedicine.18-2-138_bib61","first-page":"154","article-title":"ACC\/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"112","author":"Hunt","year":"2005","journal-title":"Circulation"},{"key":"10.7861\/clinmedicine.18-2-138_bib62","first-page":"165","article-title":"Drug therapy for heart failure in older patients-what do they want?","volume":"12","author":"Zachariah","year":"2015","journal-title":"J Geriatr Cardiol"},{"key":"10.7861\/clinmedicine.18-2-138_bib63","first-page":"535","article-title":"Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions","volume":"2","author":"Albouaini","year":"2007","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.7861\/clinmedicine.18-2-138_bib64","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/heart.89.2.225","article-title":"Chronic cor pulmonale","volume":"89","author":"Weitzenblum","year":"2003","journal-title":"Heart"},{"key":"10.7861\/clinmedicine.18-2-138_bib65","article-title":"Multidisciplinary team approach to heart failure management","author":"Morton","year":"2017","journal-title":"Heart"},{"key":"10.7861\/clinmedicine.18-2-138_bib66","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ahj.2013.01.017","article-title":"Iron deficiency in chronic heart failure: an international pooled analysis","volume":"165","author":"Klip","year":"2013","journal-title":"Am Heart J"},{"key":"10.7861\/clinmedicine.18-2-138_bib67","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.18-2-138_bib68","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jacc.2007.09.036","article-title":"Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial","volume":"51","author":"Okonko","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.7861\/clinmedicine.18-2-138_bib69","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"10.7861\/clinmedicine.18-2-138_bib70","unstructured":"70 Kalra PR,. Intravenous Iron Treatment in Patients With Heart Failure and Iron Deficiency: IRONMAN. 2017 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02642562,."},{"key":"10.7861\/clinmedicine.18-2-138_bib71","unstructured":"71 Amgen,. Registrational Study With Omecamtiv Mecarbil\/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF). 2017. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02929329,."},{"key":"10.7861\/clinmedicine.18-2-138_bib72","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrcardio.2014.83","article-title":"The pathophysiology of heart failure with preserved ejection fraction","volume":"11","author":"Borlaug","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"10.7861\/clinmedicine.18-2-138_bib73","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1001\/jama.288.17.2144","article-title":"Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure","volume":"288","author":"Kitzman","year":"2002","journal-title":"JAMA"},{"key":"10.7861\/clinmedicine.18-2-138_bib74","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.jacc.2011.06.054","article-title":"Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study","volume":"58","author":"Edelmann","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.7861\/clinmedicine.18-2-138_bib75","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/2047487314564729","article-title":"Effects of drug and exercise intervention on functional capacity and quality of life in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials","volume":"23","author":"Fukuta","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"10.7861\/clinmedicine.18-2-138_bib76","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1161\/CIRCHEARTFAILURE.110.958785","article-title":"Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial","volume":"3","author":"Kitzman","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.7861\/clinmedicine.18-2-138_bib77","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/hrt.2007.117978","article-title":"The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction","volume":"94","author":"Yip","year":"2008","journal-title":"Heart"},{"key":"10.7861\/clinmedicine.18-2-138_bib78","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10741-014-9453-8","article-title":"Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis","volume":"20","author":"Bavishi","year":"2015","journal-title":"Heart Fail Rev"},{"key":"10.7861\/clinmedicine.18-2-138_bib79","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.18-2-138_bib80","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.7861\/clinmedicine.18-2-138_bib81","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","article-title":"Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study","volume":"38","author":"Pieske","year":"2017","journal-title":"Eur Heart J"},{"key":"10.7861\/clinmedicine.18-2-138_bib82","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1001\/jama.1997.03550030052033","article-title":"Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group","volume":"278","author":"Kostis","year":"1997","journal-title":"JAMA"},{"key":"10.7861\/clinmedicine.18-2-138_bib83","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/archinternmed.2010.427","article-title":"Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk","volume":"171","author":"Sciarretta","year":"2011","journal-title":"Arch Intern Med"},{"key":"10.7861\/clinmedicine.18-2-138_bib84","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A Randomized Trial of Intensive versus Standard Blood-Pressure Control","volume":"373","author":"SPRINT Research Group","year":"2015","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.18-2-138_bib85","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824017342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824017342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.7861\/clinmedicine.18-2-138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:34:47Z","timestamp":1761460487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470211824017342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S1470211824017342"],"URL":"https:\/\/doi.org\/10.7861\/clinmedicine.18-2-138","relation":{},"ISSN":["1470-2118"],"issn-type":[{"type":"print","value":"1470-2118"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug therapies in chronic heart failure: a focus on reduced ejection fraction","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.7861\/clinmedicine.18-2-138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 Royal College of Physicians 2018. All rights reserved.","name":"copyright","label":"Copyright"}]}}